Axicabtagene ciloleucel - Biologic Drug Details

Summary for axicabtagene ciloleucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for axicabtagene ciloleucel

Recent Clinical Trials for axicabtagene ciloleucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Jennifer Crombie, MD	Phase 2
Merck Sharp & Dohme LLC	Phase 2
Stanford University	Phase 1

See all axicabtagene ciloleucel clinical trials

Pharmacology for axicabtagene ciloleucel

Mechanism of Action	CD19 Receptor Interactions
Physiological Effect	Increased T Lymphocyte Activation
Established Pharmacologic Class	CD19-directed Chimeric Antigen Receptor Genetically-modified Autologous T Cells
Chemical Structure	CD19-specific Chimeric Antigen Receptor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for axicabtagene ciloleucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for axicabtagene ciloleucel Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for axicabtagene ciloleucel Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Axicabtagene Ciloleucel

Introduction

Axicabtagene ciloleucel, marketed as YESCARTA, is a groundbreaking CD19-directed chimeric antigen receptor (CAR) T-cell therapy that has revolutionized the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Here, we delve into the market dynamics and financial trajectory of this biologic drug.

Mechanism of Action and Therapeutic Potential

Axicabtagene ciloleucel works by genetically modifying a patient's T cells to recognize and attack cancer cells expressing the CD19 antigen. This therapy has shown significant promise in clinical trials, offering improved survival rates and quality of life for patients with DLBCL[3].

Clinical Advancements and Regulatory Milestones

The drug has undergone extensive clinical trials, including the ZUMA-7 trial, which demonstrated superior efficacy of axicabtagene ciloleucel as a second-line therapy compared to standard chemo-immunotherapy. This led to the US Food and Drug Administration (FDA) expanding the label for axicabtagene ciloleucel to include its use as a second-line treatment for adults with relapsed or refractory DLBCL[1][5].

Market Forecast and Sales Projections

The market for axicabtagene ciloleucel is expected to grow significantly. A detailed market analysis forecasts strong sales up to 2032, particularly in major markets such as the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report anticipates a holistic growth trajectory driven by increasing manufacturing capacity, regulatory approvals, and expanding indications[3].

Cost-Effectiveness and Economic Impact

Cost-effectiveness analyses have shown that axicabtagene ciloleucel can be a valuable treatment option. When used as a second-line therapy, it has an incremental cost-effectiveness ratio (ICER) of $99,101 per quality-adjusted life-year (QALY) from a US health sector perspective and $97,977 per QALY from a societal perspective. These figures are below the commonly accepted willingness-to-pay threshold of $150,000 per QALY, indicating that the therapy is cost-effective in this setting[1][4].

Real-World Data and Clinical Outcomes

Real-world data from French centers have reinforced the efficacy of axicabtagene ciloleucel as a second-line therapy. Studies have reported high complete metabolic response rates and significant progression-free survival, aligning with clinical trial results and further solidifying its therapeutic value[5].

Manufacturing and Supply Chain Advancements

To meet the growing demand, manufacturers are expanding their production capacities. For instance, the development of additional adherent vector manufacturing suites is expected to enhance supply chain efficiency and support further commercial growth[2].

Competitive Landscape and Emerging Therapies

The market for DLBCL treatments is dynamic, with several emerging therapies set to challenge the current landscape. A comparative analysis of these therapies highlights the competitive advantages of axicabtagene ciloleucel, including its established efficacy and safety profile. However, new entrants, such as next-generation T-cell receptor treatments (TCR-Ts), are also gaining traction and could influence market dynamics in the future[2][3].

Financial Projections and Revenue Growth

The financial trajectory for axicabtagene ciloleucel is promising. With projected topline U.S. sales and expanding label indications, the drug is expected to generate significant revenue. For example, the market forecast suggests that YESCARTA could produce substantial operational income for its manufacturers between 2024 and 2025, driven by increased manufacturing capacity and commercial growth[2][3].

Challenges and Opportunities

Despite its potential, the high cost of axicabtagene ciloleucel remains a significant barrier to widespread adoption. Nondrug costs, such as those associated with hospital stays and managing adverse events, add to the overall expense. However, ongoing efforts to improve safety, efficacy, and manufacturing processes could make the therapy more cost-effective and accessible[4].

Regulatory and Reimbursement Implications

The cost-effectiveness of axicabtagene ciloleucel has implications for reimbursement policies and health insurance coverage. Regulatory approvals and updates, such as those from the FDA, influence the adoption of CAR T-cell therapies in clinical practice. Value assessments by bodies like the Institute for Clinical and Economic Review (ICER) play a crucial role in determining the long-term value of these therapies[1][4].

Global Market and Regional Dynamics

The global market for cell and gene therapies, including axicabtagene ciloleucel, is expected to grow, with significant activity anticipated in the European region. Regulatory checks and approvals will be critical in shaping the market dynamics in these regions[2].

Conclusion

Axicabtagene ciloleucel has established itself as a pivotal treatment for relapsed or refractory DLBCL, with a strong market and financial trajectory. Its cost-effectiveness, clinical efficacy, and expanding regulatory approvals position it for continued growth and impact in the healthcare market.

Key Takeaways

• Clinical Efficacy: Axicabtagene ciloleucel has demonstrated superior efficacy as a second-line therapy for DLBCL.
• Cost-Effectiveness: The therapy is cost-effective at a willingness-to-pay threshold of $150,000 per QALY.
• Market Forecast: Strong sales projections up to 2032 in major markets.
• Manufacturing Advancements: Expanding production capacities to meet growing demand.
• Competitive Landscape: Established efficacy and safety profile, but new therapies are emerging.
• Financial Projections: Significant revenue growth anticipated.
• Regulatory Implications: Influences reimbursement policies and health insurance coverage.

FAQs

What is axicabtagene ciloleucel used for?

Axicabtagene ciloleucel is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

How does axicabtagene ciloleucel work?

It works by genetically modifying a patient's T cells to recognize and attack cancer cells expressing the CD19 antigen.

Is axicabtagene ciloleucel cost-effective?

Yes, it is cost-effective as a second-line therapy, with an ICER below the commonly accepted willingness-to-pay threshold of $150,000 per QALY.

What are the key regulatory milestones for axicabtagene ciloleucel?

The FDA has expanded the label for axicabtagene ciloleucel to include its use as a second-line treatment for adults with relapsed or refractory DLBCL.

What are the future market projections for axicabtagene ciloleucel?

Strong sales projections up to 2032, driven by expanding manufacturing capacity, regulatory approvals, and growing demand.

Sources

1. JAMA Network Open: "Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel vs Standard Care as Second-Line or Later Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma"[1].
2. Business Wire: "Global Cell & Gene Therapy Business and Investment Opportunities Q1 2023 Update"[2].
3. GlobeNewswire: "YESCARTA (Axicabtagene Ciloleucel) Drug & Market Analysis 2023-2032"[3].
4. The American Journal of Managed Care: "Improving Outcomes and Mitigating Costs Associated With CAR T Cell Therapy"[4].
5. Blood: "Real World Data of Axicabtagene Ciloleucel As Second Line Therapy for Patients with Early Relapsed/Refractory Large B-Cell Lymphoma"[5].

Last updated: 2024-12-17